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Abstract
Methylene diphenyl diisocyanate (MDI) is among the leading chemical causes of occupational 
asthma world-wide, however, the mechanisms of disease pathogenesis remain unclear. This study 
tests the hypothesis that glutathione (GSH) reacts with MDI to form quasistable conjugates, 
capable of mediating the formation of MDI-conjugated “self” protein antigens, which may 
participate in pathogenic inflammatory responses. To test this hypothesis, an occupationally 
relevant dose of MDI (0.1% w/v) was reacted with varying concentrations of GSH (10 μM-10 
mM), and the reaction products were characterized with regard to mass/structure, and ability to 
carbamoylate human albumin, a major carrier protein for MDI in vivo. LC-MS/MS analysis of 
GSH-MDI reaction products identified products possessing the exact mass of previously described 
S-linked bis(GSH)-MDI and its partial hydrolysis product, as well as novel cyclized GSH-MDI 
structures. Upon co-incubation of GSH-MDI reaction products with human albumin, MDI was 
rapidly transferred to specific lysines of albumin, and the protein's native conformation/charge was 
altered, based on electrophoretic mobility. Three types of modification were observed, intra-
molecular MDI cross-linking, addition of partially hydrolyzed MDI, and addition of “MDI-GSH”, 
where MDI's 2nd NCO had reacted with GSH's “N-terminus”. Importantly, human albumin 
carbamoylated by GSH-MDI was specifically recognized by serum IgG from MDI exposed 
workers, with binding dependent upon the starting GSH concentration, pH, and NaCl levels. 
Together, the data define a non-enzymatic, thiol-mediated transcarbamoylating mechanism by 
which GSH may promote immune responses to MDI exposure, and identify specific factors that 
might further modulate this process.
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Methylene-diphenl diisocyanate (MD belongs to a class of commercially important low 
molecular weight (LMW) chemicals known as diisocyanates, which are essential cross-
linking agents for making polyurethane [1]. Like other diisocyanates, MDI possesses the 
potential to sensitize the immune system, leading to asthma, hypersensitivity pneumonitis 
(HP) and dermatitis [2-5]. Collectively, the diisocyanates used for polyurethane production 
are a leading chemical cause of occupational asthma in industrialized nations and regulatory 
agencies around the world have established legal occupational exposure limits [5, 6]. Within 
the last 20 years, MDI has become the most abundantly produced and consumed 
diisocyanate, for multiple reasons related to its unique physical properties [1].
The mechanisms that mediate MDI, and other diisocyanates' immunogenicity remain 
unclear, hampering efforts at prevention, diagnosis, and surveillance of exposure-induced 
disease [7]. It has been hypothesized that diisocyanates' adverse health affects are caused by 
chemical reactivity with self-molecules, especially primary amine groups of proteins, which 
are reactive under physiologic conditions [8, 9]. In vivo, albumin appears to be the major 
protein target for diisocyanate reactivity, and diisocyanate-albumin is the only known “self” 
protein reaction product known to trigger innate and adaptive cellular immune responses, 
associated with airway inflammation and asthma [10-14]. In vitro, diisocyanate-albumin 
specifically stimulates production of histamine releasing factor, and other inflammatory 
chemokines, from peripheral blood mononuclear cells of sensitized workers [13, 15, 16]. 
Diisocyanate-albumin specific IgG is frequently found in the serum of exposed workers, 
however, IgE isotypes are rarely observed (even in hypersensitive individuals), an important 
distinction between diisocyanate and common environmental asthma triggered by “high 
molecular weight” antigens [7, 14, 17-20].
The microenvironment under which albumin reacts with diisocyanat in vivo and 
subsequently induces adaptive immune responses is uncertain. Albumin molecules in airway 
surfactant, epithelial fluid, or the extracellular skin compartment may be targets for direct 
reactivity with diisocyanate [21-27]. However, data from animal studies, demonstrating 
rapid accumulation of diisocyanate-albumin conjugates in the peripheral circulation, 
following respiratory tract-only exposure [28], have suggested the possible existence of a 
“shuttle” mechanism (see below) [29], through which diisocyanate is transported from the 
airways to the blood, where albumin is the dominate protein (reactant).
In addition to albumin, MDI and other diisocyanates are thought to react in vivo with the tri-
peptide, γ-glutamyl-cysteinyl-glycine, also known as GSH [30, 31]. GSH is the principal 
nonprotein thiol compound in most mammalian cells, where it is present in millimolar 
concentrations [32]. GSH is also the major free thiol of the lower airway fluid, where it is 
normally present at relatively high levels (100 - 800 μM) compared with peripheral blood 
(∼1 μM) [33-36]. The epidermal layer of the skin, another potential route of diisocyanate 
exposure, also contains relatively high levels of GSH, compared with the underlying dermis 
[37].
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The reaction of isocyanate with thiols, such as GSH, is reversible, prompting the theory that 
GSH serves as a shuttle for systemic distribution of inhaled diisocyanate [29, 38-40]. 
Evidence supporting a “shuttling” capacity of GSH has been derived largely from in vitro 
studies of toluene diisocyanate (TDI) and aryl mono-isocyanates, demonstrating that GSH 
conjugates can carbamoylate other peptides/proteins, including albumin [11, 38, 41, 42]. In 
contrast, GSH mediated transcarbamoylation of MDI, which possesses unique physical 
properties compared with other mono- and di-isocyanates, remains relatively under-studied. 
Furthermore, the hypothetically key pathogenic aspect of GSH-mediated carbamoylation 
with MDI, or other diisocyanates, i.e. modification of proteins in an antigenic manner, e.g. 
rendering them recognizable by the host immune system [43, 44], has yet to be 
demonstrated for humans.
In this study, we investigate the hypothetical mechanism whereby GSH serves as a 
carbamoylating intermediate (e.g. shuttle) in the conjugation of albumin by MDI, and 
identify specific reaction conditions that further modulate this process. The experimental 
strategy builds upon limited published data on GSH reactivity with MDI, and other aryl 
mono-isocyanates, which largely used NMR to characterize thiol-MDI conjugation and 
disassociation [41, 45, 46]. The present investigation utilizes a combination of LC-MS/MS 
and electrophoretic analyses to further characterize GSH-MDI reaction products and their 
unique modification of human albumin, under physiological exposure conditions (neutral 
pH, normal saline, temperature, aqueous solvent). The biologic relevance of MDI-albumin 
conjugates, generated via GSH-mediated transcarbamoylation, was further evaluated based 
on specific binding of serum IgG from MDI exposed workers. The potential contribution of 
GSH toward MDI-specific immunologic responses is discussed based on the experimental 
findings.
2. Materials and Methods
2a. Reagents
The following chemicals and proteins were obtained from Sigma-Aldrich (St. Louis, MO): 
reduced and oxidized forms of glutathione, GSH (CAS # 70-18-8) and GSSH (CAS # 
27025-41-8) respectively, and 4,4′-methylenebis(phenyl isocyanate), or MDI (CAS # 
101-68-8), human albumin, transferrin, thioredoxin, and ovalbumin from turkey egg white. 
GSH, GSSG, MDI and protein reagents were of ≥98.0% purity. Buffer reagents, which 
included mono- and di-basic sodium phosphate, sodium chloride, citric acid, sodium citrate, 
bicarbonate, sodium carbonate, and deionized water were also from Sigma.
2b. GSH-MDI reactions
Glutathione solutions of varying concentrations were initially prepared in 20 mM sodium 
phosphate buffer with or without NaCl, and in later experiments in 0.1 M citrate or 
carbonate buffer. Freshly prepared stock solutions of 10% MDI (w/v) in acetone (JT Baker; 
Phillipsburg, NJ) were added to GSH solution drop-wise with stirring, to achieve 0.1% MDI 
final concentration, or approximately 4mM MDI, well below the starting concentrations of 
chemical (50%) typically aerosolized to generate spray foam insulation [6]. Reactions were 
allowed to proceed at 37°C, with end-over-end mixing, for 2 hrs, and then pelleted at 10,000 
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× g and 0.2 μm syringe filtered. Reaction products were immediately tested for 
carbamoylating activity, or snap frozen and stored at −80°C until analyzed by mass 
spectrometry. In all experiments, negative controls included reactions identically performed 
for 2 hours with (a) MDI in buffer without GSH (MDI-buffer control), and in some 
experiments (b) substituting GSSG for GSH (GSSG-MDI). Preliminary data (not show) 
demonstrated that MDI at 0.1% w/v in PBS was completely hydrolyzed/polymerized within 
2 hours in the absence of GSH (e.g. MDI-buffer control sample).
2c. LC-MS/MS analysis of GSH-MDI reaction products
Total GSH-MDI reactions were dried. via SpeedVac and re-constituted with 50 μL water. 
Next, 15 μL of the re-constituted sample was diluted with 19 μL water, 1 μL acetonitrile and 
5 μL of 1% formic acid. Samples were then desalted using a C18 ZipTip, and eluted into 
50ul 60% acetonitrile/0.1% formic acid. Five uL of the de-salted samples were then directly 
infused via Advion TriVersa NanoMate into a Bruker 9.4T FT-ICR MS [47].
2d. Protein carbamoylation by GSH-MDI
Following sterile filtration (0.2 μM), total GSH-MDI reaction products were mixed 1:2 with 
a solution of human albumin at 5 mg/ml in phosphate buffered without NaCl, or phosphate 
buffer with NaCl (PBS), each containing 20 mM phosphate. In some experiments 0.1M 
citrate, or 0.1M bicarbonate, were used to alter the pH. Albumin and GSH-MDI reaction 
products were co-incubated at 37°C for 1hr, after which time the solution was chilled to 
4°C, dialyzed, and subsequently analyzed for MDI modification by MS/MS and 
electrophoresis, or antigenicity based on specific recognition by serum IgG from MDI 
exposed workers. For all experiments control samples were tested to ensure that MDI 
conjugation of albumin was occurring via GSH reaction products, and not via direct 
reactivity with MDI. Thus, controls included albumin co-incubated with MDI that was 
“mock reacted” with GSH-free buffer v (MDI-buffer control, see above), or GSSG (MDI-
GSSG). In some experiments, the proteins transferrin, thioredoxin, or ovalbumin were 
substituted for human albumin in carbamoylation reactions.
2e. LC-MS/MS analysis of albumin carbamoylated by GSH-MDI
Samples of albumin carbamoylated by GSH-MDI, were reduced, acetylated, and trypsin 
digested, prior to LC-MS/MS at the Yale University Keck Center, as previously described 
[47, 48]. Samples were run on an LTQ Orbitrap Elite mass spectrometer and all MS/MS 
spectra were searched using the automated Mascot algorithm against the NCBInr database. 
A 95% confidence level was set within the MASCOT search engine for protein hits based on 
randomness search. In addition, 2 or more MS/MS spectra must have matched the same 
protein entry and been derived from trypsin digestion. Peptide scores >20 are likely correct 
based on past experience, and the higher the score the better the match. In addition to 
oxidation of methionine and acetylation (carbamidomethyl) of cysteine during workup, the 
data were further queried for expected mass modifications (see Fig. 3) due to 
carbamoylation by GSH-MDI reaction product(s) (Figs. 1-3).
Wisnewski et al. Page 4













2f. Electrophoretic analysis of albumin carbamoylated by GSH-MDI
For analysis of gel electrophoretic mobility under native conditions (which increases upon 
MDI conjugation), samples were prepared in a glycerol buffer, and run on 10% 
polyacrylamide gels. Following electrophoresis, gels were stained with Imperial protein 
stain from Pierce (Rockford, IL).
2g. Human subjects
The study was approved by Yale University's Institutional Review Board for human subject 
investigation. All subjects provided informed written consent, and answered questionnaires 
related to MDI or other diisocyanate exposures. Study subjects included 3 construction 
workers who reported spraying MDI-based foam insulation >4 hrs/day, >3 days/week for >6 
months, and were diagnosed with occupational asthma by a pulmonologist. An additional 12 
individuals, without MDI exposure, were enrolled as control subjects. Ten milliliters of 
blood were obtained from each subject by venipuncture, using red top tubes with serum 
separators from Becton-Dickinson (Franklin Lakes, NJ). Following centrifugation at 1000 × 
g for 10 minutes, serum was separated from clotted blood, 0.2 μm syringe filtered 
(Millipore, Bedford, MA), aliquoted and stored at −80°C.
2h. Antigenicity of proteins carbamoylated by GSH-MDI
ELISAs were performed initially to test the antigenicity of albumin carbamoylated via GSH, 
based on specific recognition by serum IgG from MDI exposed workers vs. unexposed 
individuals [9]. Maxisorp® microtiter plates from Nunc (VWR International) were 
incubated overnight at 4°C with 5 μg/well of human albumin that had been co-incubated 
with MDI-GSH reaction products, as described above. Plates were coated in 0.1 M 
carbonate buffer, pH 9.5, washed, and “blocked” with 3% (w/v) dry milk/PBS, before 
addition of human serum samples diluted 1:200 (v/v) in 3% dry milk/PBS/0.05% Tween 20. 
Following washes and incubation with secondary reagent, peroxidase-conjugated anti-
human IgG Fc (Pharmingen; San Diego, CA), diluted 1:2000 (v/v), ELISA plates were 
developed with tetramethylbenzidine substrate. Optical density (OD) measurements 
(absorbance of light at 450 nm, minus absorbance at a reference wavelength) were obtained 
on a Benchmark microtiter plate reader from Bio-Rad (Hercules, CA). All experiments were 
repeated three times to obtain mean and standard error values. Statistical differences in IgG 
binding data were calculated using the Wilcoxon rank-sum test.
In some ELISA experiments, albumin and other proteins, carbamoylated by GSH-MDI, 
were probed for recognition by human serum IgG (as above), or for the presence of MDI, 
using MDI-specific mAbs [49], in which case peroxidase conjugated anti-mouse IgG was 
substituted for anti-human IgG as the secondary reagent.
3. Results
a. Reaction of GSH with MDI in aqueous phase
To begin evaluating the interaction of GSH with MDI, reactions were performed under 
aqueous phase conditions established in previous studies [9]. When an occupationally-
relevant concentration of MDI, 0.1% (w/v) or 4 mM, was reacted with 10 mM GSH, e.g. a 
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slight (25%) molar excess of SH vs. NCO, LC-MS analysis indicated multiple products, 
with m/z's ranging from 483.13 to 1314.11 (Fig. 1 and Table 1). Two of the reaction 
products possessed masses identical to the previously described (bis)GSH-MDI, and its 
partial hydrolysis product (mono)GSH-MDI*, where the * indicates MDI's unbound 
N=C=O hydrolyzed to a primary amine [45]. Several additional products were also 
observed, with m/z's consistent with GSH-MDI containing one or more GSH and/or MDI 
groups with varying degrees of hydrolysis, as listed in Table 1. Molecular modeling of the 
products, based on their exact mass and LC-MS/MS (not shown), suggests several different 
cyclized structures (Figure 2) for those products with the strongest relative intensity. It 
remains unclear if these novel GSH-MDI products form directly, or if they result from 
secondary reactions of bis(GSH)-MDI and/or mono(GSH)-MDI*.
3b. Ability of GSH-MDI reaction products to carbamoylate human albumin
The ability of GSH-MDI reaction products to carbamoylate human albumin, a major carrier 
protein for MDI in vivo, was evaluated through FT-ICR-MS/MS analysis of trypsin-digested 
albumin samples that had been co-incubated with GSH-MDI. Experiments were performed 
with GSH starting concentrations of 10 mM, as described above, and 10-fold lower levels of 
GSH (e.g. 1 mM), which are closer to those present in the airway lining fluid in vivo. 
Carbamoylated albumin peptides were detected by querying the data for exact masses 
expected to result from (A) addition of partially hydrolyzed MDI, (B) intra-molecular cross-
linking with MDI, or (C) addition of MDI-GSH, as depicted in Figure 3. The data identified 
eight lysine modifications when albumin was co-incubated with GSH-MDI prepared with 1 
mM GSH in PBS (Table 2, and supplemental data), but not control samples. Carbamoylation 
with partially hydrolyzed MDI (modification A, Figure 3), or intra-molecular cross-linking 
by MDI (modification B, Figure 3), was most prominent on lysines that comprise di-lysine 
motifs, which account for 4 of the 8 modification sites, and are also preferred sites for direct 
MDI-albumin conjugation [9, 50]. In contrast, cyclized GSH-MDI appeared to preferentially 
carbamoylate sites (K162, and K545), distinct from those preferentially targeted by direct 
MDI reactivity [9, 50]. When albumin carbamoylation was performed with GSH-MDI 
prepared with a higher starting concentration of GSH (10 mM) in phosphate buffer without 
NaCl, an additional 5 sites of modification were observed (Table 2, and supplemental data).
3c. GSH-MDI mediated changes in human albumin's charge/conformation
MDI-albumin formed via GSH-MDI was electrophoresed in acrylamide gels to characterize 
differences in migration that reflect changes in albumin's charge/conformation. As 
highlighted in Fig. 4A, carbamoylation via GSH-MDI increased albumin's electrophoretic 
mobility towards the anode under native conditions, suggesting a net increase in negative 
charge. Notably, the electrophoretic migration of human albumin carbamoylated by GSH-
MDI differed from that of MDI-albumin generated via direct exposure (using same starting 
dose of MDI for GSH and albumin exposure). Despite changes in electrophoretic migration 
in native gels, no differences were observed in SDS-PAGE gels comparing control albumin 
samples vs. MDI-albumin resulting from transcarbamoylation via GSH (data not shown).
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3d. Antigenicity of albumin carbamoylated by GSH-MDI reaction products
The antigenicity of MDI-albumin, resulting from carbamoylation via GSH-MDI, was 
evaluated based on recognition by human antibodies in Western blot and ELISAs, using sera 
from human subjects with and without MDI exposure, described in Table 3. As shown (Figs 
4B and 5A), serum IgG from MDI exposed workers (N=3), but not unexposed individuals 
(N=12), displayed substantial binding to MDI-albumin, prepared via GSH-MDI.
The antigenicity (i.e. specific recognition by serum IgG from MDI exposed workers) of 
MDI-albumin, formed via GSH-MDI, was highly depended upon the reaction conditions, 
especially the starting GSH concentration, pH, and presence/absence of NaCl. When GSH 
was prepared in phosphate buffered saline (PBS), a dose-dependent relationship was 
observed between the starting GSH concentration and the antigenicity of the final 
carbamoylation product (e.g. MDI-albumin). Antigen formation reached maximum levels 
when the starting GSH concentration was 1mM, but decreased as the GSH concentration 
was further heightened (Fig 5B). In the absence of NaCl the “dose-response curve” was 
shifted to the right. When GSH was prepared in unbuffered solution (water), limited MDI 
reactivity/transcarbamoylation was observed, which may be due to GSH's innately low pH, 
and the acid-stability of thiol-cyanate reaction products [41, 51]. Consistent with this 
hypothesis, higher pH levels during the carbamoylation reaction (co-incubation of albumin 
with GSH-MDI), resulted in MDI-albumin products with relatively increased antigenicity 
(Fig 5C). Under optimal conditions, MDI-albumin conjugates resulting from GSH-mediated 
transcarbamoylation exhibited antigenicity (based on workers' serum IgG binding in ELISA) 
comparable to albumin directly reacted with MDI (Fig 4B and not shown).
In additional studies, the ability of GSH-MDI to carbamoylate human proteins other than 
human albumin, and the potential antigenicity of such MDI-proteins, were evaluated. ELISA 
data (Fig. 5D) using MDI-specific mAbs, demonstrated the capacity of GSH-MDI to 
carbamoylate a number of different proteins including thioredoxin, transferrin, and 
ovalbumin. However, serum IgG from the MDI exposed workers did not recognize these 
other MDI-protein conjugates despite the presence of IgG that recognized similarly 
generated MDI-albumin.
4. Discussion
This study defines a non-enzymatic transcarbamoylating mechanism through which GSH 
mediates the formation of antigenic diisocyanate-albumin conjugates, which have been 
implicated in pathogenic responses (cytokine production, specific IgE, oxidative stress, 
innate immune proteins) to occupational exposure [12, 14, 15, 46, 52-54]. The findings 
expand upon our understanding of MDI's potential reactivity with self-molecules present at 
exposure sites, and describe novel (cyclized) GSH-MDI reaction products that form under 
physiologic conditions. The transfer of isocyanate groups, from GSH to albumin, as 
described here, highlight the complex chemical-protein interactions that may underlie MDI's 
immunogenic capacity in vivo. The data support previous theories implicating GSH as a 
shuttle for isocyanate, which could explain systemic distribution, and chemical conjugation 
of proteins distant from the exposure site. The data also describe exposure conditions that 
modify GSH-MDI reactivity and subsequent carbamoylation of albumin, which may explain 
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individual differences in exposure responses, and serve as the basis for disease prevention/
intervention strategies.
The present data expand upon studies by Reissner et al, which described the selective 
formation of thiol-linked mono and bis(GSH)-MDI under relatively non-physiologic 
anhydrous conditions, e.g. at −25°C, in organic solvent, with starting concentrations of 
160mM GSH and 10 mM MDI [45]. In this study, mono and bis(GSH)-MDI reaction 
products were observed under more natural exposure conditions, e.g. aqueous solution, 
37°C, neutral pH, isotonic saline, physiological GSH concentration and 2.5-fold lower MDI 
levels. Additional cyclized GSH-MDI reaction products were observed, with MDI 
conjugated to both the SH and the “amino terminus” of GSH. It remains unclear if, these 
novel cyclized structures result from direct MDI reactivity or via secondary reactions of 
mono(GSH)-MDI* and bis(GSH)-MDI.
Multiple exposure variables were shown to influence the formation and stability of GSH-
MDI reaction products, and their subsequent transfer of MDI to albumin, including GSH 
concentration, pH, and ionic composition of the reaction buffer. At the occupationally 
relevant MDI concentration tested (e.g. 0.1% w/v), the dose-response relationship (between 
starting GSH concentration and ultimate MDI-albumin antigenicity) was non-linear, 
increasing with GSH concentration to a maximum point, and then decreasing at higher GSH 
levels. Notably, under isotonic conditions (e.g. PBS), formation of antigenic MDI-albumin 
occurred at GSH concentrations within the range (100 μM - 1 mM) found in the lower 
airway fluid [33, 34]. The pH was also an important factor in GSH-mediated 
transcarbamoylation of albumin, consistent with classic descriptions of thiol-cyanate 
linkages [40], and the previously described pH-sensitivity of S-linked MDI-cysteine, TDI-
GSH, and other monoisocyanate-GSH conjugates [11, 41, 51]. The effect of pH, as well as 
NaCl, on GSH carbamoylation of human albumin is intriguing with respect to the 
differences in composition of exposure sites vs. internal tissues, e.g. airway fluid, 
(intra)cellular, skin, plasma [55]. Together, the data suggest potential mechanisms by which 
individual variability in airway fluid GSH concentration, ionic composition, and pH, could 
influence the immune response to isocyanate exposure, by affecting the formation of 
antigenic MDI-albumin conjugates.
MDI-albumin conjugates formed via GSH were found to possess important similarities and 
differences compared to MDI-albumin resulting from direct MDI exposure. GSH-MDI and 
direct MDI exposure both, induced changes in albumin's electrophoretic migration and 
targeted specific lysine residues, resulting in covalent intra-molecular cross-linking, and 
conjugation with partially hydrolyzed MDI. However, MDI-albumin formed via GSH also 
contained a unique modification apparently resulting from a cyclized GSH-MDI 
intermediate, in which MDI effectively cross links GSH to albumin via GSH's γ-glutamine. 
Further studies will be necessary to determine if/how the unique structural modification with 
MDI-γ-glu-cys-gly affects albumin's antigenicity compared with MDI cross-linking or 
conjugation with partially hydrolyzed MDI.
During the course of the present investigation we found that proteins other than human 
albumin (e.g. transferrin, thioredoxin) also underwent MDI conjugation via GSH, but were 
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not then recognized by serum IgG from exposed workers. These data are consistent with 
previously published MDI serology, demonstrating the importance of albumin as a “carrier 
protein” for humoral immune recognition of isocyanate [9, 14]. However, the data also 
suggest possible mechanisms by which GSH-mediated carbamoylation with MDI could 
contribute to pathologic immune responses without necessarily evoking chemical-specific 
immunoglobulin, for example, by altering the functional activity of local airway proteins. 
Cell membrane proteins, especially those that normally metabolize GSH-conjugates, might 
be especially sensitive targets for MDI transcarbamoylation, and their functional modulation 
could evoke inflammation secondary to redox signaling [36].
Limitations of the present study design should be recognized in considering the possible 
significance of the data, with regard to MDI exposure in vivo. Attention was focused on the 
potential influence of “biological” variation (e.g. GSH concentration, pH) given a defined 
occupationally-relevant exposure dose (e.g. 0.1% w/v MDI), rather than variation in 
exposure dose. The impact of MDI dose on GSH reactivity and carbamoylating capacity will 
require further study. The lability of GSH-MDI reaction products, including their 
susceptibility to hydrolysis and potential secondary reactions, limited quantitative analysis 
of reaction kinetics and complicated product identification and characterization. 
Measurement of GSH-mediated, MDI-transfer to albumin, and the different types of lysine 
modification (e.g. cross-linking, partially hydrolyzed MDI, MDI-γ-glu-cys-gly) were also 
quantitatively limited, with analysis focused more towards qualitative documentation of 
antigenicity and associated changes in conformational/charge. One of the major GSH-MDI 
reaction products previously described, bis(GSH)-MDI, reportedly possesses limited 
solubility in aqueous solution, which may account for some of the differences in the present 
data compared with previous studies [45, 46].
The influence of GSH concentration on MDI carbamoylation, as described here, warrants 
further technical consideration, given clinical reports suggesting therapeutic potential of 
glutathione supplementation for multiple medical conditions [56-59]. The present findings, 
that very high GSH levels (Figure 5B and data not show) resulted in decreased amounts of 
antigenic MDI-albumin formation, could be due to the influence of GSH on the pH of the in 
vitro reaction. At concentrations above 1 mM, GSH begins to override the buffering 
capacity of PBS, decreasing the pH, and thus, stabilizing S-linked GSH-isocyanate bonds 
(i.e. preventing carbamoylation). Furthermore, excessive amounts of unreacted GSH may 
act as a competitive inhibitor of albumin carbamoylation. Ultimately, in vivo studies should 
help clarify the potential effect of GSH concentration on MDI reactivity, which may 
represent a mechanism for modifying biological responses to occupational exposure.
In summary, the present findings describe a non-enzymatic, thiol-mediated 
transcarbamoylating process through which GSH can mediate the formation of MDI-
albumin conjugates under physiologic conditions (neutral pH, isotonic saline). MDI-albumin 
conjugates, generated via GSH-mediated transcarbamoylation exhibit distinct changes in 
conformation/charge compared with unexposed albumin, and possess unique structures (e.g. 
addition of MDI-GSH, as shown in Fig 3C) compared with albumin directly reacted with 
MDI. Perhaps most importantly, MDI-albumin conjugates generated via GSH-mediated 
transcarbamoylation are specifically recognized by serum IgG of exposed workers. 
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Together, the data define a possible mechanistic role for GSH as a “shuttle” for MDI, 
leading to the formation of antigenic MDI-albumin reaction products, and define specific 
variables that may modulate this process.
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MDI methylene diphenyl diisocyanate
MDI* partially hydrolyzed methylene diphenyl diisocyanate
TDI toluene diisocyanate
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Interaction of GSH with an important occupational allergen (MDI) is investigated
GSH-MDI reaction products carbamoylate human albumin, altering conformation/
charge
GSH mediated transcarbamoylation of human albumin (with MDI) causes antigenic 
changes
The data define a potential mechanistic role for GSH in MDI asthma pathogenesis
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Figure 1. LC-MS analysis of GSH-MDI reaction products
Ten millimolar GSH was reacted with 0.1% MDI in phosphate buffer without NaCl for 2 
hrs, microfuged and 0.2 μM filtered before LC-MS. Panel A shows m/z range 200-1200, 
while panels B, C and D highlight more limited regions. Arrows highlight major products 
described further in Table 1 and Figure 2 including the previously described mono(GSH)-
MDI and bis(GSH)-MDI, indicated with an * in Panel A.
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Figure 2. Proposed chemical structures for GSH-MDI reaction products
The structures of some of the reaction products identified in Figure 1/Table 1 are predicted 
based on their exact mass.
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Figure 3. Expected modifications via GSH-MDI
Addition to albumin (via the isocyanate group shown on the left side), of the structures 
show, should increase the mass (by the values shown) of peptides resulting from trypsin 
digestion. Note additional (non-isocyanate) modification in sub-panel C, which may occur 
during sample processing (e.g. acetylation as circled).
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Figure 4. Changes in albumin's charge/conformation and antigenicity after carbamoylation by 
GSH-MDI
Panel A. Total protein stain of native gels analyzing human albumin carbamoylated by 
GSH-MDI reaction products prepared with 1 mM GSH/PBS (lane 1), 10 mM GSH/
phosphate w/out NaCl (lane 2), or directly reacted with 0.1% MDI (lane 3). Lanes 4 to 6 
contain control albumin samples, mock exposed or co-incubated with control GSH or MDI 
samples (see Materials and Methods for more information). Panel B. Parallel Western blot 
probed with pooled serum from (N=3) MDI exposed workers. No binding was observed 
with sera from unexposed subjects (not shown). Arrows highlight differences in 
electrophoretic migration, which reflect changes in charge and/or conformation.
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Figure 5. Antigenicity of albumin carbamoylated by GSH-MDI
Human albumin carbamoylated by GSH-MDI, or control albumin, were used to coat ELISA 
plates for studies with human sera. The ELISA optical density (O.D.) readings (Y-axis), 
which reflect IgG binding, provide a measure of antigenicity. Panel A. Serum (1:100) IgG 
binding to MDI-albumin, resulting from transcarbamoylation via 1 mM GSH/PBS, is 
compared for (N=12) unexposed subjects vs. (N=3) MDI exposed workers. Panel B. 
Albumin carbamoylated by GSH-MDI prepared with varying levels of GSH starting 
concentration (X-axis) in different buffers (as labeled) was tested for antigenicity using 
pooled sera (1:100 dilution) from MDI exposed workers. Dashed line shows highest O.D. 
values observed with control serum from unexposed subjects and * indicates significantly (p 
< 0.05) increased O.D. vs. pooled sera from unexposed subjects (not shown). Panel C. GSH-
mediated carbamoylation of human albumin was performed at different pH levels (X-axis), 
and subsequently tested for antigenicity with individual serum samples. Panel D. Different 
proteins, including human albumin (alb), transferrin (trans), thioredoxin (thio), or ovalbumin 
(ova) were carbamoylated by 1 mM GSH/PBS reaction products, and subsequently tested by 
ELISA using pooled sera from MDI exposed workers, or anti-MDI monoclonal antibodies.
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Table 1
List of GSH-MDI reaction products observed by LC-MS
mass charge m/z Predicted Product
483.1341 1+ 483.1341 GSH-MDI (cy)b without glycinec
532.1872 1+ 532.1872 GSH-MDI*aaka mono(GSH)-MDI
558.1667 1+ 558.1667 GSH-MDI (cy)
378.6449 2+ 756.2831 GSH-MDI*-MDI* or *MDI-GSH-MDI*
756.2831 1+ 756.2831 *MDI-GSH-MDI*
782.2619 1+ 782.2619 GSH-MDI*-MDI (cy)
865.2502 1+ 865.2502 GSH-MDI-GSH aka bis(GSH)-MDI
507.6608 2+ 1014.3143 GSH-MDI-GSH-MDI* without glycine
1014.3143 1+ 1014.3143 GSH-MDI-GSH-MDI* without glycine
1040.2947 1+ 1040.2947 GSH-MDI-GSH-MDI without glycine
545.1770 2+ 1089.3540 GSH-MDI-GSH-MDI*
1089.3458 1+ 1089.3458 GSH-MDI-GSH-MDI*
1115.3243 1+ 1115.3243 GSH-MDI-GSH-MDI (cy)
657.2248 2+ 1314.1124 GSH-MDI-GSH-MDI*-MDI (cy)
a
* indicates N=C=O group hydrolyzed to NH2
b
(cy) denotes possible cyclic structure as shown in Figure 2
c
products without glycine may be contaminant of GSH, but can also fragment from parent compound, as observed in MS/MS spectra (not shown).
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Table 2
Sites and types of human albumin modification by GSH-MDI
Exposure Conditions [GSH], buffer Modification
-MDI* (Δ = 224mu) -MDI- (Δ = 250mu) -MDI-GSH (Δ = 614mu)
1 mM GSH PBS K137, K351 K414, K525, K541 K524, K525 K162, K545
10 mM GSH H2PO4−/HPO42− K136, K137, K351 K190, K199 K414, 
K525, K545
K190, K199, K541 K162, K545 K20, K323, K402
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Table 3
Basic Demographics & Exposure Information of Study Subjects
MDI Exposed Workers Unexposed Control Subjects
Total (N) 3 12
Gender: (M/F) 3/0 10/2
Age (avg. ± SE) 41 ± 9 37 ± 11
Total IgE (avg. ± SE) 56 ± 41 94 ± 138
Current smoker (Y/N) 1/2 4/8
Occupational MDI use* +++ -
MDI skin contact** +++ -
Years MDI Exposure*** (avg. ± SE) 3.1 ± 1.7 -
*
Occupational MDI use according to questionnaire data. (+) = yes, (-) = no in response to “Do you spray polyurethane insulation? > 4hrs/day, >3 
days/week, >6 months.”
**
MDI skin contact according to questionnaire data (+++) = frequently, (-) = never in response to “Do you get isocyanate product on your skin?”
***
Years MDI exposure according to questionnaire data. “Total number of years spraying polyurethane foam insulation.” (-) = none
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